Skip to content
Comparison

Ozempic vs Mounjaro

Ozempic and Mounjaro are commonly compared for type 2 diabetes with concurrent obesity. Ozempic is usually favored for cardiovascular outcomes maturity and semaglutide familiarity, while Mounjaro is often preferred for greater glycemic and weight-loss potency in SURPASS. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For type 2 diabetes with concurrent obesity, the better choice depends on your primary endpoint. Ozempic is stronger when the priority is patients prioritizing semaglutide evidence continuity. Mounjaro is stronger when the priority is patients targeting stronger A1C and weight response. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaOzempicMounjaro
Primary mechanismGLP-1 receptor agonist (semaglutide) for glycemic controlDual GIP/GLP-1 agonist (tirzepatide) for diabetes
Strongest clinical signal~1.5-2.0% A1C reduction; moderate weight loss in diabetes cohorts~2.0%+ A1C reductions and substantial weight loss
Typical dosing context0.25 mg start, titrated to 1-2 mg weekly2.5 mg start, titrated to 5-15 mg weekly
AdministrationWeekly subcutaneous injectionWeekly subcutaneous injection
Evidence quality gradeStrong for type 2 diabetes; moderate for obesity at Ozempic dosesStrong SURPASS diabetes evidence
Regulatory statusFDA-approved for type 2 diabetesFDA-approved for type 2 diabetes
Side-effect burdenGI effects common; boxed thyroid C-cell warningGI effects during titration, generally manageable
Cost/access contextHigh list price; insurance-dependent accessHigh list price; payer criteria vary
Best candidate profileT2D patients needing cardio-metabolic risk reductionT2D with obesity where stronger efficacy is needed
Main limitationWeight-loss ceiling lower than obesity-dose pathwaysCoverage and supply may be variable
Best use case in this comparisonpatients prioritizing semaglutide evidence continuitypatients targeting stronger A1C and weight response

When to Choose Each

Choose Ozempic

Best for patients prioritizing semaglutide evidence continuity.

Choose Mounjaro

Best for patients targeting stronger A1C and weight response.

Verdict

If the main goal is patients prioritizing semaglutide evidence continuity, Ozempic is usually the better first-line choice. If the main goal is patients targeting stronger A1C and weight response, Mounjaro is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (2021) — PubMed
  2. Semaglutide and cardiovascular outcomes in patients with obesity (SELECT trial) (2023) — PubMed
  3. Oral semaglutide versus subcutaneous liraglutide in type 2 diabetes (PIONEER 4) (2019) — PubMed
  4. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER trial) (2016) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Hims & HersMost Popular

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

From $199/moLearn More →
Henry MedsMost Peptides

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

From $249/moLearn More →
Ro BodyBest Value

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

From $149/moLearn More →

Sponsored · Affiliate Disclosure

Frequently Asked Questions

Which has stronger evidence for type 2 diabetes with concurrent obesity — Ozempic or Mounjaro?
Ozempic is graded as strong for type 2 diabetes; moderate for obesity at ozempic doses evidence in this context, while Mounjaro is graded as strong surpass diabetes evidence. In practice, strength depends on whether you prioritize patients prioritizing semaglutide evidence continuity or patients targeting stronger A1C and weight response. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can Ozempic and Mounjaro be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next